Search the Newsreel

BioMarin (BMRN) Is Up 5.6% After Raising 2026 Revenue Outlook and Filing ESOP Shelf Registration

BioMarin Pharmaceutical (BMRN) Updates Guidance And Files Shelf Registration, Is It Still Below Fair Value?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. BioMarin Pharmaceutical (BMRN) has just given investors a packed update, including second quarter 2026 results, fresh earnings guidance for the rest of the …

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Rating of "Moderate Buy" from Brokerages

Top Generate Biomedicines (GENB) Competitors 2026

Is BioMarin Pharmaceutical (BMRN) Still Cheap As 2026 Guidance Rises And Amicus Adds Growth?

BioMarin Pharmaceutical (BMRN) has updated its 2026 guidance and completed the Amicus acquisition, leading to increased attention on the stock. Despite strong short-term momentum and a "22% Undervalued" narrative, the article highlights the need for investors to consider inherent risks, such as reliance on …

Zimmer Biomet - ZIM - Stock Price & News

This article provides a detailed financial overview of Zimmer Biomet (ZIM), a company specializing in orthopedic reconstructive products. It includes stock performance metrics, market capitalization, key financial ratios like revenue, net income, and EPS, along with annual and quarterly growth comparisons. The content also …

Everett Harris & Co. CA Invests $2.55 Million in Zimmer Biomet Holdings, Inc. $ZBH

Everett Harris & Co. CA recently acquired a new stake of 29,647 shares, valued at approximately $2.55 million, in Zimmer Biomet Holdings, Inc. during the second quarter. Other institutional investors have also adjusted their holdings in ZBH, which currently has 88.89% institutional ownership. Zimmer …

Orchestra BioMed (OBIO) director uses 5,145 shares to cover RSU tax withholding

Orchestra BioMed Holdings, Inc. director Eric S. Fain reported an indirect disposition of 5,145 common stock shares on August 12, 2026. These shares were withheld by the company to satisfy tax withholding obligations related to the vesting of restricted stock units (RSUs) and no …

Orchestra BioMed (OBIO) director withholds 3,761 shares to cover RSU tax bill

Orchestra BioMed (OBIO) director has 4,885 shares withheld for RSU tax

Orchestra BioMed (OBIO) director reports 4,238 RSU tax-withholding shares

Biomea Fusion (NASDAQ:BMEA) Gains Attention As Institutions Expand Exposure

Biomea Fusion (NASDAQ:BMEA) is attracting renewed market interest due to increased institutional investment. The company, a clinical-stage biopharmaceutical firm focusing on precision therapies for cancer and metabolic diseases, sees its outlook driven by clinical execution, regulatory progress, and financial management. Its strategy centers on …

Highbridge Capital (AXIN) discloses 9.1% holding in Axiom Intelligence Class A

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is BioMarin Pharmaceutical (BMRN) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector …

Research Analysts Offer Predictions for OBIO Q3 Earnings

Are Wall Street Analysts Bullish on Zimmer Biomet Stock?

Zimmer Biomet headquarters_By jetcityimage Zimmer Biomet Holdings, Inc. (ZBH), headquartered in Warsaw, Indiana, designs, manufactures, and sells medical equipment. Valued at $18.7 billion by market cap, the company offers orthopedic, dental, and spinal reconstructive implants, as well as bone cement and related surgical products. …

5 Revealing Analyst Questions From Zimmer Biomet’s Q2 Earnings Call

5 Revealing Analyst Questions From Zimmer Biomet's Q2 Earnings Call Zimmer Biomet's second quarter results were driven by strong execution in its hip franchise, robust technology sales, and progress in the U.S. sales force transformation. CEO Ivan Tornos highlighted that new product adoption, such …

Zacks.com featured highlights include BioMarin Pharmaceutical, Invesco, Centene Corporation, Hewlett Packard Enterprise and Gibraltar Industries

For Immediate Release Chicago, IL – August 14, 2026 – Stocks in this week's article are BioMarin Pharmaceutical BMRN, Invesco IVZ, Centene Corporation CNC, Hewlett Packard Enterprise HPE and Gibraltar Industries ROCK. 5 Undervalued Price-to-Book Stocks Worth Buying in August There are several different …

Handelsbanken Fonder AB Buys 28,130 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Handelsbanken Fonder AB increased its stake in Zimmer Biomet Holdings, Inc. by 22.7% in the second quarter, purchasing an additional 28,130 shares to bring its total to 152,064 shares valued at approximately $13.1 million. Zimmer Biomet exceeded Q2 earnings expectations with $2.07 EPS and …

Bubs Australia (ASX:BUB) Expands US Infant Nutrition Growth After EBITDA Turnaround

Biome Australia (ASX:BIO) Expands Probiotic Brand Growth With Record Sales

Barclays PLC discloses 1.23M Axiom Intelligence (AXIN) shares on Schedule 13G

Glazer Capital details 7.77% Axiom stake in AXIN Units (AXIN)

Glazer Capital, LLC and Paul J. Glazer have reported a beneficial ownership of 1,600,072 Units in Axiom Intelligence Acquisition Corp 1 (AXIN), representing 7.77% of the outstanding class. The filing specifies that all voting and dispositive power over these securities is shared, with no …

Zimmer Biomet (ZBH) sees Dodge & Cox disclose 12.5% ownership stake

Dodge & Cox has filed an amended Schedule 13G, revealing a 12.5% beneficial ownership stake in Zimmer Biomet Holdings, Inc. (ZBH), as of June 30, 2026. This represents 24,124,735 shares, with Dodge & Cox holding sole voting power over 22,808,935 shares and sole dispositive …

Axiom Intelligence (AXIN) inks Terra Quantum deal amid going concern warning

Axiom Intelligence Acquisition Corp 1 (AXIN) has reported total assets of $208.3 million as of June 30, 2026, and a net income of $2.27 million for the six months ended June 30, 2026, primarily from interest on trust investments. The SPAC has entered into …

Axiom Intelligence Acquisition Corp 1 Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Biomea Fusion doses first patient in icovamenib-semaglutide study

Biomea Fusion, Inc. (NASDAQ:BMEA) has dosed the first patient in a new arm of its OPAL platform study, evaluating the combination of icovamenib and low-dose semaglutide. This randomized double-blind study aims to assess whether adding icovamenib can enhance weight loss and improve physical function, …

Generate Biomedicines (GENB) Stock Price, News & Analysis

Generate Biomedicines (NASDAQ: GENB) utilizes machine learning and generative AI for novel therapeutic design and discovery. The company recently reported Q2 2026 earnings, missing analyst estimates, and has a "Moderate Buy" consensus rating with a price target of $25.40, suggesting a 62.4% upside. Its …

Wall Street Analysts Are Bullish on Top Healthcare Picks

Wall Street analysts are showing bullish sentiment towards two healthcare stocks: Orchestra BioMed Holdings (OBIO) and Adagene (ADAG). H.C. Wainwright reiterated a Buy rating for Orchestra BioMed with a $10.00 price target, while LifeSci Capital maintained a Buy rating for Adagene with an $8.00 …

Will Zimmer Biomet’s Upgraded 2026 Guidance and Buyback Shift Zimmer Biomet Holdings’ (ZBH) Narrative

Zimmer Biomet Holdings (ZBH) reported strong Q2 2026 results, including US$2,177 million in sales and US$198.3 million in net income, alongside completing a US$496.84 million share buyback. Management also raised full-year guidance due to robust performance in its hip and technology segments. This move …

Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Orchestra BioMed Holdings, Inc. (OBIO) recently reported Q2 results showing revenues significantly below expectations, though statutory losses were in line with forecasts. Analysts have since updated their models, projecting a substantial 99% reduction in 2026 revenues and an increase in per-share losses, indicating a …

Biomea Fusion doses first patient in icovamenib-semaglutide study By Investing.com

Biomea Fusion has announced the dosing of the first patient in a new arm of its OPAL platform research study. This study will evaluate icovamenib in combination with low-dose semaglutide against semaglutide alone for individuals who are overweight or obese but do not have …

Biomea Fusion Trial Tests Obesity Drug Combo Beyond Weight Loss

Biomea Fusion has dosed the first patient in a new arm of its OPAL study, evaluating icovamenib in combination with low-dose semaglutide for overweight or obese adults without type 2 diabetes. The study, in collaboration with the University of Leicester, aims to assess whether …